-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Previous studies have shown that amyloid beta (Aβ) deposition in the brain is an early neurological change in Alzheimer's disease (AD) patients
.
However, the pathogenesis of AD is not well explained
Recent evidence suggests a potential role for the gut microbiota (GM) in the development or exacerbation of AD
There is increasing evidence that the gut and central nervous system (CNS) interact through the following neurochemical pathways
Data were sourced from the PubMed, MEDLINE, Scopus and Cochrane Libraries from January 2000 to August 2021, including pre-intervention data from observational trials and intervention trials investigating the abundance of GM in AD-lineage patients and HCs
.
Effect size calculations were performed by random effects, inverse variance weighted models
Eleven studies consisting of 378 HC and 427 AD spectrum patients were included in the meta-analysis
.
AD patients showed a marked reduction in GM diversity compared with HC, whereas MCI did not
AD patients showed a marked reduction in GM diversity compared with HC, whereas MCI did not
Shannon's index for comparisons between healthy controls (HC) and Alzheimer's disease (AD) pedigrees
In the HC and AD lineages, the abundance profiles of Alistipes and Bacteroides were affected differently by country
.
Finally, when the clinical stage was considered as a moderating factor, a comparison of Clostridium and Fareobacteriaceae abundances showed a larger effect size, with a gradient from MCI to AD stage
When clinical stage was considered as a moderating factor, a comparison of Clostridium and Fareobacteriaceae abundances showed a larger effect size, with a gradient from MCI to AD stages
CONCLUSIONS: Patients with AD spectrum showed altered GM abundance, which was mediated differently in different countries and clinical stages
references:
Gut microbiota in patients with Alzheimer's disease spectrum: a systematic review and meta-analysis.
Gut microbiota in patients with Alzheimer's disease spectrum: a systematic review and meta-analysis.
Leave a comment here
